5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methyl-phenol | 100134-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methyl-phenol
• 英文别名: 5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methylphenol
• CAS: 100134-37-0
• 化学式: C₁₂H₁₄N₂O
• 分子量: 202.256
• InChiKey: XXPUQOFRUJNXFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  15.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48.91
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  乙酰丙酮 在 哌啶 、 乙醇 、 一水合肼 作用下， 反应 2.0h， 生成 5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methyl-phenol
  参考文献：
  名称：

  Ultrasonographic, Axial, and Peripheral Measurements in Female Patients with Benign Hypermobility Syndrome

  摘要：

  Twenty-five female Caucasians, aged 19-57 years, with the hypermobility syndrome had bone density measurements using established noninvasive techniques such as dual X-ray absorptiometry (DXA), single photon absorptiometry (SPA), heel ultrasound (US), and peripheral computed tomography (pQCT) acquisitions of the radius. As a group, comparisons of the different bone indices with the corresponding age-matched reference population resulted in normal z-scores for the arial densities, however, values for the volumetric total and cortical bone at the radius measured by pQCT were significantly lower than expected (P < 0.0001). Spinal and femoral bone density results were significant after correction for body mass index (BMI). This cross-sectional study shows that the benign hypermobility syndrome patients have lowered t-scores for data reflecting bone structure and bone strength as measured with US and the tomographic technique.

  DOI：

  10.1007/s00223001093